{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:54:29Z","timestamp":1762160069850},"reference-count":148,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,7,7]],"date-time":"2003-07-07T00:00:00Z","timestamp":1057536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunological Reviews"],"published-print":{"date-parts":[[2003,8]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold> Multiple myeloma (MM) affects 15\u2003000 new patients annually in the US, with 50\u2003000 total patients, and remains incurable. Our preliminary <jats:italic>in vitro<\/jats:italic> and animal studies suggest a role for MM\u2013host interactions in regulating MM cell growth, drug resistance, and migration in the bone marrow. Importantly, treatment strategies which target mechanisms whereby MM cells grow and survive in the bone marrow, including thalidomide and its potent immunomodulatory derivatives and proteasome inhibitor PS\u2010341, can overcome classical drug resistance in preclinical and early clinical studies.<\/jats:p>","DOI":"10.1034\/j.1600-065x.2003.00053.x","type":"journal-article","created":{"date-parts":[[2003,7,7]],"date-time":"2003-07-07T09:20:30Z","timestamp":1057569630000},"page":"164-176","source":"Crossref","is-referenced-by-count":73,"title":["Novel therapeutic approaches for multiple myeloma"],"prefix":"10.1111","volume":"194","author":[{"given":"Teru","family":"Hideshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,7]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.334"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_2_12_5_2","first-page":"7","article-title":"Impact on survival of high\u2010dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population\u2010based study","volume":"95","author":"Lenhoff S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90014-9"},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.4008"},{"key":"e_1_2_12_8_2","first-page":"815a","article-title":"In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABST) transplantation using unselected of CD34 enriched ABSC: preliminary results or a two by two designed randomized trial in 230 young patients with multiple myeloma (MM)","volume":"98","author":"Fermand JP","year":"2001","journal-title":"Blood"},{"key":"e_1_2_12_9_2","first-page":"5a","article-title":"Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the \u2018Intergroupe Francophone du Myelome\u2019 (IMF94)","volume":"100","author":"Attal M","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.673.414k30_673_683"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110313251802"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02726.x"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.934"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2574"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0131"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34070"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc746"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90021-6"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70413-5"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1658"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203782"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.9.2306.2306"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.12.3712.3712"},{"key":"e_1_2_12_25_2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion\u2010induced interleukin\u20106 expression in bone marrow stromal cells involves activation of NF\u2010\u03baB","volume":"87","author":"Chauhan D","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.5.1928.1928"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204623"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402295"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.5.2212"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.227"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.48.29995"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203082"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.428"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205664"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204833"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109068200"},{"key":"e_1_2_12_38_2","first-page":"539","article-title":"The biologic sequelae of stromal cell\u2010derived factor\u20101a in multiple myeloma","volume":"1","author":"Hideshima T","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.7.1903.bloodjournal8571903"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01101.x"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70115-5"},{"key":"e_1_2_12_42_2","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin\u20106 in paracrine tumor\u2013stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar B","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1874"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80011-4"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204733"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9940"},{"key":"e_1_2_12_48_2","first-page":"4262","article-title":"Inhibition of JAK kinase activity enhances Fas\u2010mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells","volume":"7","author":"Oshiro MM","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_12_49_2","first-page":"6763","article-title":"The phosphatidylinositol 3\u2010kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine\u2010dependent survival and proliferative responses","volume":"60","author":"Tu Y","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_12_50_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100074200"},{"key":"e_1_2_12_51_2","doi-asserted-by":"crossref","first-page":"27845","DOI":"10.1074\/jbc.M003428200","article-title":"SHP2 mediates the protective effect of interleukin\u20106 against dexamethasone\u2010induced apoptosis in multiple myeloma cells","volume":"275","author":"Chauhan D","year":"2000","journal-title":"J Biol Chem"},{"key":"e_1_2_12_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205205"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009620027205"},{"key":"e_1_2_12_54_2","unstructured":"ChauhanD et al.Identification of genes regulated by 2\u2010methoxyestradiol (2ME2) in multiple myeloma (MM) cells using oligonucleotide array.Blood(in press)."},{"key":"e_1_2_12_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/35085509"},{"key":"e_1_2_12_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0008"},{"key":"e_1_2_12_57_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","article-title":"The development of a model for the homing of multiple myeloma cells to human bone marrow","volume":"90","author":"Urashima M","journal-title":"Blood"},{"key":"e_1_2_12_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x"},{"key":"e_1_2_12_59_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4721018.x"},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R"},{"key":"e_1_2_12_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.765.bloodjournal853765"},{"key":"e_1_2_12_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.0.CO;2-X"},{"key":"e_1_2_12_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03231.x"},{"key":"e_1_2_12_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(95)00085-2"},{"key":"e_1_2_12_65_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF\u2010\u03b1","volume":"163","author":"Corral LG","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_12_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc952"},{"key":"e_1_2_12_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1419"},{"key":"e_1_2_12_68_2","first-page":"5019","article-title":"The vascular endothelial growth factor receptor kinase inhibitor PTK787\/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment","volume":"62","author":"Lin B","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2856"},{"key":"e_1_2_12_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.4138"},{"key":"e_1_2_12_71_2","first-page":"3876","article-title":"Cytokines modulate telomerase activity in a human multiple myeloma cell line","volume":"62","author":"Akiyama M","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_72_2","first-page":"170a","article-title":"The IGF\/IGF\u20101R system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors","volume":"100","author":"Mitsiades CS","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_73_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood.V85.9.2521.bloodjournal8592521","article-title":"Interleukin\u201010 is a proliferation factor but not a differentiation factor for human myeloma cells","volume":"85","author":"Lu ZY","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_74_2","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","article-title":"Interleukin\u201010 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop","volume":"88","author":"Gu ZJ","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_75_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1\u2010\u03b1 is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi SJ","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_76_2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)\u20101\u03b1 and MIP\u20101beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe M","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01510.x"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.610"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3756"},{"key":"e_1_2_12_80_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.6.1801"},{"key":"e_1_2_12_81_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1343"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_12_83_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.3.699"},{"key":"e_1_2_12_84_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.6.1675"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.2.408"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1997.0292"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(99)70206-0"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"e_1_2_12_91_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_12_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201253"},{"key":"e_1_2_12_93_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310269"},{"key":"e_1_2_12_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_12_95_2","first-page":"2300","article-title":"S\u20103\u2010Amino\u2010phthalimido\u2010glutarimide inhibits angiogenesis and growth of B\u2010cell neoplasias in mice","volume":"62","author":"Lentzsch S","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_96_2","first-page":"816a","article-title":"Pre\u2010clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors \u2013 ENMD\u20100995 (S\u2010(\u2013)\u20103\u2010(3\u2010amino\u2010phthalimido)\u2010glutarimide)","volume":"100","author":"Treston AM","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90079-9"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.4065\/75.9.897"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"e_1_2_12_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"e_1_2_12_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"e_1_2_12_103_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1652"},{"key":"e_1_2_12_104_2","first-page":"1","article-title":"Proteasome inhibitors: from research tools to drug candidates","volume":"21","author":"Kisselv AF","year":"2001","journal-title":"Chem Biol"},{"key":"e_1_2_12_105_2","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"e_1_2_12_107_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543"},{"key":"e_1_2_12_108_2","first-page":"4996","article-title":"Proteasome inhibitor PS\u2010341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc R","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_12_109_2","doi-asserted-by":"crossref","unstructured":"MitsiadesN et al.The proteasome inhibitor PS\u2010341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood101:2377\u20132380.","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_12_110_2","unstructured":"HideshimaT et al.Caspase\u2010dependent cleavage of gp130\/interleukin\u20106 receptor b\u2010subunit in multiple myeloma: therapeutic implications(submitted for publication)."},{"key":"e_1_2_12_111_2","first-page":"104a","article-title":"A phase II multicenter study of the proteasome inhibitor Bortezomib (Velcade\u2122, formerly PS\u2010341) in multiple myeloma patients (pts) with relapsed\/refractory disease","volume":"100","author":"Richardson P","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_112_2","first-page":"851","article-title":"Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"1","author":"Hayashi T","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00105-3"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:4:239"},{"key":"e_1_2_12_115_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.805"},{"key":"e_1_2_12_116_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3964"},{"key":"e_1_2_12_117_2","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2\u2010methoxyestradiol and taxol","volume":"57","author":"Klauber N","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_12_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0376"},{"key":"e_1_2_12_119_2","first-page":"813a","article-title":"Induction of apoptosis by lysophosphatidic acid acyltransferase (LPAAT)\u2010\u03b2 inhibitors in multiple myeloma (MM)","volume":"100","author":"Hideshima T","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_120_2","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies","volume":"59","author":"Bellamy WT","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_12_121_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.14.6403"},{"key":"e_1_2_12_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200111000-00009"},{"key":"e_1_2_12_123_2","first-page":"1438","article-title":"Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines","volume":"7","author":"Adjei AA","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_12_124_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3361"},{"key":"e_1_2_12_125_2","first-page":"376a","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cell lines and patient tumor cells","volume":"98","author":"Mitsiades N","year":"2001","journal-title":"Blood"},{"key":"e_1_2_12_126_2","first-page":"106a","article-title":"LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: results of a pre\u2010clinical evaluation in vitro and in vivo","volume":"100","author":"Catley L","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_127_2","first-page":"377a","article-title":"The HSP90 molecular chaperone as a novel therapeutic target in hematologic malignancies","volume":"98","author":"Mitsiades CS","year":"2001","journal-title":"Blood"},{"key":"e_1_2_12_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630207"},{"key":"e_1_2_12_129_2","first-page":"839","article-title":"Bcl\u20102 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells","volume":"13","author":"Gazitt Y","year":"1998","journal-title":"Int J Oncol"},{"key":"e_1_2_12_130_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729002760220798"},{"key":"e_1_2_12_131_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.13.7566"},{"key":"e_1_2_12_132_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M909695199"},{"key":"e_1_2_12_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(00)00413-0"},{"key":"e_1_2_12_134_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.795"},{"key":"e_1_2_12_135_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2162"},{"key":"e_1_2_12_136_2","first-page":"4262","article-title":"Cytokines prevent dexamethasone\u2010induced apoptosis via the activation of mitogen\u2010activated protein kinase and phosphatidylinositol 3\u2010kinase pathways in a new multiple myeloma cell line","volume":"60","author":"Ogawa M","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_12_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402501"},{"key":"e_1_2_12_138_2","first-page":"597a","article-title":"HMG\u2010CoA inhibitors (statins) induce growth arrest, apoptosis of multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) cells and enhance their sensitivity to conventional or novel therapies. Molecular profiling of HMG\u2010CoA inhibition in MM\/WM and framework for translation to therapeutic application","volume":"100","author":"Mitsiades CS","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200201000-00008"},{"key":"e_1_2_12_140_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1487"},{"key":"e_1_2_12_141_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2992"},{"key":"e_1_2_12_142_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202491499"},{"key":"e_1_2_12_143_2","doi-asserted-by":"publisher","DOI":"10.1038\/13928"},{"key":"e_1_2_12_144_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<215::AID-IJC12>3.0.CO;2-Q"},{"key":"e_1_2_12_145_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.7.2411"},{"key":"e_1_2_12_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70027-9"},{"key":"e_1_2_12_147_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1669"},{"key":"e_1_2_12_148_2","first-page":"399a","article-title":"Dendritic cell (DC)\u2010tumor fusions generated with mature as compared to immature DC potently induce myeloma specific immunity","volume":"100","author":"Grosman DD","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_149_2","first-page":"400a","article-title":"Ex vivo induction of multiple myeloma\u2010specific cytotoxic T lymphocytes","volume":"100","author":"Hayashi T","year":"2002","journal-title":"Blood"}],"container-title":["Immunological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-065X.2003.00053.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-065X.2003.00053.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-065X.2003.00053.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:27:56Z","timestamp":1697236076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-065X.2003.00053.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,7]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["10.1034\/j.1600-065X.2003.00053.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-065x.2003.00053.x","archive":["Portico"],"relation":{},"ISSN":["0105-2896","1600-065X"],"issn-type":[{"value":"0105-2896","type":"print"},{"value":"1600-065X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,7]]}}}